cjc-1295 dac ipamorelin (NO DAC) + – Research Peptide CJC-1295 No DAC & Ipamorelin

Contraindications Not recommended for individuals with active cancer or untreated endocrine disorders without medical supervision

Progressive abdominal distension or waist increase that cannot be explained by training/nutrition

Growth hormone secretagogues (GHSs) and GHRH analogues Agents such as GHRH analogues and ghrelin receptor agonists (e.g., tesamorelin, macimorelin, ipamorelin and related molecules) stimulate endogenous GH release rather than providing recombinant GH itself

Tesamorelins pivotal trials tested reduction of excess visceral (abdominal) fat in people with HIV-associated lipodystrophy, and that is its FDA-approved indication

(to offset changes in REM sleep, insulin fasting levels cortisol & blood glucose level) because if the supplements are the train the peptides are the conductor- IOWs one doesnt really work well without the other & sometimes you even have to pair / stack peptides in order to control the desired impact / outcome